CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC

SUZHOU, China, June 2, 2024 /PRNewswire/ — CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and…

Related Keywords

China ,Switzerland ,United Kingdom ,Suzhou ,Jiangsu ,Jason Yang ,European Medicines Agency ,Regulatory Agency ,Committee For Medicinal Products Human Use ,Cstone Pharmaceuticals ,European Commission ,Drug Administration ,National Medical Products Administration ,Central Eastern Europe ,Medicinal Products ,Human Use ,Executive Director ,Lancet Oncology ,Nature Cancer ,Combined Positive Score ,Transl Lung Cancer Res ,